Novartis set to sell stake in Roche?
Novartis would consider selling its 20% stake in fellow Swiss firm Rocheif they cannot agree on some kind of cooperation, according to the former's chief executive Daniel Vasella. In an interview with the German newspaper Handelsblatt, he said "we can't, and don't want to, force anyone into cooperating."
If there are no joint interests for the two companies to follow, "a profitable divestment would be the obvious choice," Dr Vasella was quoted as saying. At the moment, there are no talks taking place with Roche over a possible collaboration accord and no pressing plans on the part of Novartis to sell the stake, he added. Novartis bought the stake from Martin Ebner's BZ group earlier this year (Marketletter May 14).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze